Journal
LIFE-BASEL
Volume 13, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/life13091847
Keywords
SARS-CoV-2; microbiota; microbiome; bacteria; probiotics
Categories
Ask authors/readers for more resources
Studies have found that Bifidobacterium may provide protection against COVID-19 by reducing symptoms, improving lung function, reducing inflammation, and alleviating gastrointestinal symptoms. The genus may also modulate the immune response, compete with pathogenic microbes, and maintain gut barrier function to combat the disease.
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, mainly causes respiratory and intestinal symptoms and changes in the microbiota of patients. We performed a systematic search in major databases using Bifidobacterium and COVID-19 or SARS-CoV-2 as key terms to assess the relationship of the genus to COVID-19. After the selection steps, 25 articles were analyzed. Of these, eighteen were observational, and seven were interventional articles that evaluated the use of Bifidobacterium alone or in mix as probiotics for additional treatment of patients with COVID-19. All stages and severities were contemplated, including post-COVID-19 patients. Overall, Bifidobacterium was associated with both protective effects and reduced abundance in relation to the disease. The genus has been found to be abundant in some cases and linked to disease severity. The studies evaluating the use of Bifidobacterium as probiotics have demonstrated the potential of this genus in reducing symptoms, improving pulmonary function, reducing inflammatory markers, alleviating gastrointestinal symptoms, and even contributing to better control of mortality. In summary, Bifidobacterium may offer protection against COVID-19 through its ability to modulate the immune response, reduce inflammation, compete with pathogenic microbes, and maintain gut barrier function. The findings provide valuable insights into the relationship between the disease and the genus Bifidobacterium, highlighting the potential of microbiota modulation in the treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available